Escolar Documentos
Profissional Documentos
Cultura Documentos
ABSTRACT This paper seeks to highlight Mexicos interest in being at the forefront in
Latin America and at the same time at the international level with the major players in the
field of biotech medicines. Mexico has just adopted an amendment to the General Health
Law that would allow the regulatory approval of biocomparable drugs (some countries refer
to these as biosimilar or biogeneric drugs). Such reform consists in the incorporation of
Article 222 Bis, which describes what is regarded as a biotechnology medicine, distinguishes
between innovative and biocomparable medicines, sets the requirements to obtain sanitary
registration and for marketing, describes the regulations regarding the pharmacovigilance
of these products, as well as the studies that are necessary to demonstrate the quality, safety
and efficacy of a biocomparable medicine which is supported with reference to an innovative
medicine, and taking into consideration the Opinion of the Committee of New Molecules
through the Subcommittee for the Evaluation of Biotechnology Products. This amendment
also includes the assignment of the same International Non-propriety Name (INN) as for
the reference product. The goal of the reform is to encourage competitiveness in Mexico by
regulating the manufacture and approval of these medicines making them more affordable
and hence fostering their access to the population.
Journal of Generic Medicines (2010) 7, 47. doi:10.1057/jgm.2009.38; published online 10 November 2009
Keywords: innovative biotechnological medicines; biocomparable medicines; amendment to Article
222 Bis of the general health law; access to biotech medicines at affordable prices
WHAT ARE
BIOTECHNOLOGICAL
MEDICINES?
Biotechnological medicines contain proteins
with very complex and unstable structures,
Correspondence: Ernesto Saro Boardman
Paseo de la Reforma 136, Torre Azul, Floor 15, Oficina A Col.
Jurez Del. Cuauhtmoc, CP 06600, Mexico, DF
E-mail: ernesto.saro@pan.senado.gob.mx
www.palgrave-journals.com/jgm/
Downloaded from jgm.sagepub.com at The University of Hong Kong Libraries on February 4, 2016
NEGOTIATION AND
REGULATION IN MEXICO
Biotechnological medicines appeared almost
three decades ago and have revolutionized the
methods for treating serious diseases like
cancer. Mexico, in particular, has welcomed
the pharmaceutical industry for this purpose.
Although it is certain that these drugs are
highly effective for fighting against deadly
diseases, it is also true that they are the most
expensive drugs in the market, which makes
them inaccessible to the population, to such a
degree that the treatment for one person for
1 year can cost up to US$300.000.1
However, patents granted to the
manufacturers of biotechnology medicines
throughout this time have already begun to
expire, so competition of biocomparable
drugs should start providing consumers
greater access to these important but
expensive drugs. Before 2009, such
approvals were not regulated in the
Mexican legal system extending the facto
the patents of such products.
Given the technical complexity involved in
defining a legal process for the approval of
biocomparable medicines, scientists, academics,
physicians, health authorities, legislators,
representatives of national and international
industries were convened to participate in
Downloaded from jgm.sagepub.com at The University of Hong Kong Libraries on February 4, 2016
Saro Boardman
Downloaded from jgm.sagepub.com at The University of Hong Kong Libraries on February 4, 2016
REFERENCE
1. New York Times. (2008) When a drug costs
$300 000. Editorial 23 March.
Downloaded from jgm.sagepub.com at The University of Hong Kong Libraries on February 4, 2016